No information is available on the use of revumenib during breastfeeding. Because it is 90% bound to plasma proteins, the amount in milk is likely to be very low. The manufacturer recommends that breastfeeding be discontinued during therapy and for 1 week after the last dose.
关于瑞武尼布在母乳喂养期间的使用尚无可用信息。由于它与血浆蛋白的结合率为90%，乳汁中的含量可能非常低。制造商建议在治疗期间及最后一剂后1周内停止母乳喂养。
